Parkinson Disease, Late-Onset (PARK) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Mental diseases, Metabolic diseases

Aliases & Classifications for Parkinson Disease, Late-Onset

Aliases & Descriptions for Parkinson Disease, Late-Onset:

Name: Parkinson Disease, Late-Onset 54 38 69
Parkinson Disease 54 23 50 24 25 66 52 42 69
Parkinson's Disease 38 50 25 51 29 41
Late Onset Parkinson Disease 12 66 29 14
Primary Parkinsonism 50 25 66
Paralysis Agitans 50 66
Pd 25 66
Parkinson Disease, Late-Onset, Susceptibility to 13
Idiopathic Parkinson Disease 66
Lewy Body Parkinson Disease 66
Shaking Palsy 50
Park 66



parkinson disease, late-onset:
Inheritance sporadic
Onset and clinical course progressive insidious onset


External Ids:

OMIM 54 168600
Disease Ontology 12 DOID:0060892
MeSH 42 D010300
ICD10 33 G20

Summaries for Parkinson Disease, Late-Onset

OMIM : 54 Parkinson disease was first described by James Parkinson in 1817. It is the second most common neurodegenerative... (168600) more...

MalaCards based summary : Parkinson Disease, Late-Onset, also known as parkinson disease, is related to parkinson disease 6, early onset and multiple system atrophy, and has symptoms including constipation, dystonia and bradykinesia. An important gene associated with Parkinson Disease, Late-Onset is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Chks in Checkpoint Regulation. The drugs Rasagiline and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include Brain and Brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Genetics Home Reference : 25 Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.

NIH Rare Diseases : 50 parkinson disease belongs to a group of conditions called movement disorders. the four main symptoms are tremor, or trembling in hands, arms, legs, jaw, or head; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance. these symptoms usually begin gradually and worsen with time.  as they become more pronounced, patients may have difficulty walking, talking, or completing other simple tasks.  not everyone with one or more of these symptoms has parkinson disease, as the symptoms sometimes appear in other diseases as well. parkinson disease affects about 1 to 2 percent of people over the age of 60 years and the chance of developing parkinson disease increases as we age. although some parkinson disease cases appear to be hereditary most cases are sporadic and occur in people with no apparent history of the disorder in their family. when three or more people are affected in a family, especially if they are diagnosed at an early age (under 50 years)  there may be a gene making this family more likely to develop the condition. currently, seven genes that cause some form of parkinson's disease have been identified. mutations (changes) in three known genes called snca (park1),uchl1 (park 5), and lrrk2 (park8) and another mapped gene (park3) have been reported in families with dominant inheritance. mutations in three known genes, park2 (park2), park7 (park7), and pink1 (park6) have been found in affected individuals who had siblings with the condition but whose parents did not have parkinson's disease (recessive inheritance). there is some research to suggest that these genes are also involved in early-onset parkinson's disease (diagnosed before the age of 30) or in dominantly inherited parkinson's disease but it is too early yet to be certain. however, in most cases inheriting a mutation will not cause someone to develop parkinson's disease because there may be additional genes and environmental factors determining who will get the condition, when they get it and how it affects them.  last updated: 11/5/2015

MedlinePlus : 41 parkinson's disease (pd) is a type of movement disorder. it happens when nerve cells in the brain don't produce enough of a brain chemical called dopamine. sometimes it is genetic, but most cases do not seem to run in families. exposure to chemicals in the environment might play a role. symptoms begin gradually, often on one side of the body. later they affect both sides. they include trembling of hands, arms, legs, jaw and face stiffness of the arms, legs and trunk slowness of movement poor balance and coordination as symptoms get worse, people with the disease may have trouble walking, talking, or doing simple tasks. they may also have problems such as depression, sleep problems, or trouble chewing, swallowing, or speaking. there is no lab test for pd, so it can be difficult to diagnose. doctors use a medical history and a neurological examination to diagnose it. pd usually begins around age 60, but it can start earlier. it is more common in men than in women. there is no cure for pd. a variety of medicines sometimes help symptoms dramatically. surgery and deep brain stimulation (dbs) can help severe cases. with dbs, electrodes are surgically implanted in the brain. they send electrical pulses to stimulate the parts of the brain that control movement. nih: national institute of neurological disorders and stroke

NINDS : 51 Parkinson's disease (PD) belongs to a group of conditions called motor system disorders, which are the result of the loss of dopamine-producing brain cells. The four primary symptoms of PD are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination. As these symptoms become more pronounced, patients may have difficulty walking, talking, or completing other simple tasks. PD usually affects people over the age of 60.  Early symptoms of PD are subtle and occur gradually.  In some people the disease progresses more quickly than in others.  As the disease progresses, the shaking, or tremor, which affects the majority of people with PD may begin to interfere with daily activities.  Other symptoms may include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions.  There are currently no blood or laboratory tests that have been proven to help in diagnosing sporadic PD.  Therefore the diagnosis is based on medical history and a neurological examination.  The disease can be difficult to diagnose accurately.   Doctors may sometimes request brain scans or laboratory tests in order to rule out other diseases.

UniProtKB/Swiss-Prot : 66 Parkinson disease: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

Wikipedia : 71 Parkinson\'s disease (PD) is a long-term degenerative disorder of the central nervous system that mainly... more...

GeneReviews: NBK1223

Related Diseases for Parkinson Disease, Late-Onset

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 7, Autosomal Recessive Early-Onset Parkinson Disease 6, Early Onset
Parkinson Disease 19, Juvenile-Onset Parkinson Disease 10
Parkinson Disease 16 Parkinson Disease 13
Parkinson Disease 11 Parkinson Disease 21
Parkinson Disease 18 Parkinson Disease 5
Parkinson Disease 4 Parkinson Disease 1
Parkinson Disease, Juvenile, Type 2 Parkinson Disease 8
Parkinson Disease 17 Parkinson Disease 20, Early-Onset
Parkinson Disease 15, Autosomal Recessive Parkinson Disease 14, Autosomal Recessive
Parkinson Disease 12 Juvenile Onset Parkinson Disease 19a
Juvenile-Onset Parkinson Disease Early-Onset Parkinson Disease
Lrrk2-Related Parkinson Disease Parkinson Disease Type 3
Parkinson Disease Type 9 Dnajc6-Related Parkinson Disease
Eif4g1-Related Parkinson Disease Gigyf2-Related Parkinson Disease
Pla2g6-Related Parkinson Disease Synj1-Related Parkinson Disease
Fbxo7-Related Parkinson Disease Htra2-Related Parkinson Disease
Park7-Related Parkinson Disease Snca-Related Parkinson Disease
Vps35-Related Parkinson Disease Hereditary Late-Onset Parkinson Disease
Parkinson Disease 22 Parkinson Disease 23, Autosomal Recessive, Early Onset

Diseases related to Parkinson Disease, Late-Onset via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 106)
id Related Disease Score Top Affiliating Genes
1 parkinson disease 6, early onset 33.8 LRRK2 PARK7 PINK1
2 multiple system atrophy 32.1 MAOB PARK7 PINK1 SNCA
3 personality disorder 32.0 DRD2 MAPT SLC6A3 SNCA
4 parkes weber syndrome 12.3
5 parkinson disease, juvenile, type 2 12.3
6 parkinson disease 4 12.2
7 parkinson disease 15, autosomal recessive 12.2
8 parkinson disease 1 12.1
9 parkinson disease 17 12.1
10 parkinson disease 18 12.1
11 parkinson disease 19, juvenile-onset 12.1
12 parkinson disease 5 12.1
13 parkinson disease 20, early-onset 12.1
14 parkinson disease 14, autosomal recessive 12.1
15 parkinson disease 7, autosomal recessive early-onset 12.0
16 parkinson disease 8 12.0
17 parkinson disease 21 12.0
18 postencephalitic parkinson disease 12.0
19 parkinson disease 11 12.0
20 paralysis agitans, juvenile, of hunt 12.0
21 parkinson disease 22 12.0
22 parkinson disease 13 12.0
23 parkinson disease 23, autosomal recessive, early onset 12.0
24 lrrk2-related parkinson disease 12.0
25 parkinson disease 10 11.9
26 pink1 type of young-onset parkinson disease 11.9
27 parkin type of early-onset parkinson disease 11.9
28 early-onset parkinson disease 11.9
29 hereditary late-onset parkinson disease 11.9
30 parkinson disease type 3 11.9
31 parkinson disease susceptibility 11.8
32 juvenile onset parkinson disease 19a 11.8
33 pla2g6-related parkinson disease 11.8
34 parkinson disease 16 11.8
35 snca-related parkinson disease 11.8
36 parkes weber syndrome, rasa1-related 11.8
37 parkinson disease 12 11.8
38 eif4g1-related parkinson disease 11.8
39 gigyf2-related parkinson disease 11.8
40 htra2-related parkinson disease 11.8
41 mt-tt related parkinson disease susceptibility 11.8
42 parkinson disease type 9 11.7
43 fbxo7-related parkinson disease 11.7
44 prolidase deficiency 11.5
45 pendred syndrome 11.3
46 atxn2-related parkinson disease susceptibility 11.1
47 gba-related parkinson disease susceptibility 11.1
48 corticobasal degeneration 11.0
49 spondylodysplastic ehlers-danlos syndrome 10.9
50 erythroleukemia, familial 10.9

Comorbidity relations with Parkinson Disease, Late-Onset via Phenotypic Disease Network (PDN): (show top 50) (show all 52)

Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Alzheimer Disease
Anxiety Disorder Atypical Depressive Disorder
Autonomic Nervous System Disease Bipolar Disorder
Blepharitis Bronchitis
Bronchopneumonia Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Chronic Myocardial Ischemia Communicating Hydrocephalus
Conjunctivitis Cystitis
Decubitus Ulcer Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dysthymic Disorder Encephalopathy
Erythematosquamous Dermatosis Esophagitis
Fecal Incontinence Generalized Atherosclerosis
Generalized Dystonia Heart Disease
Hypothyroidism Intestinal Volvulus
Iron Deficiency Anemia Leukodystrophy
Major Affective Disorder-7 Marasmus
Mood Disorder Neurogenic Bladder
Obstructive Hydrocephalus Osteoporosis
Paralytic Ileus Paranoid Schizophrenia
Pernicious Anemia Personality Disorder
Prostatic Hypertrophy Protein-Energy Malnutrition
Pseudobulbar Palsy Schizophrenia
Schizophreniform Disorder Swallowing Disorders

Graphical network of the top 20 diseases related to Parkinson Disease, Late-Onset:

Diseases related to Parkinson Disease, Late-Onset

Symptoms & Phenotypes for Parkinson Disease, Late-Onset

Symptoms by clinical synopsis from OMIM:


Clinical features from OMIM:


Human phenotypes related to Parkinson Disease, Late-Onset:

32 (show all 22)
id Description HPO Frequency HPO Source Accession
1 constipation 32 HP:0002019
2 dystonia 32 HP:0001332
3 bradykinesia 32 HP:0002067
4 personality changes 32 HP:0000751
5 depression 32 HP:0000716
6 dysarthria 32 HP:0001260
7 dysphagia 32 HP:0002015
8 sleep disturbance 32 HP:0002360
9 dysautonomia 32 HP:0002459
10 hallucinations 32 HP:0000738
11 mask-like facies 32 HP:0000298
12 rigidity 32 HP:0002063
13 dementia 32 HP:0000726
14 weak voice 32 HP:0001621
15 parkinsonism 32 HP:0001300
16 postural instability 32 HP:0002172
17 neuronal loss in central nervous system 32 HP:0002529
18 urinary urgency 32 HP:0000012
19 short stepped shuffling gait 32 HP:0007311
20 resting tremor 32 HP:0002322
21 lewy bodies 32 HP:0100315
22 substantia nigra gliosis 32 HP:0011960

UMLS symptoms related to Parkinson Disease, Late-Onset:

angina pectoris, back pain, headache, myoclonus, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, equilibration disorder, sleeplessness, constipation, muscle rigidity, sleep disturbances, bradykinesia, hyposmia

MGI Mouse Phenotypes related to Parkinson Disease, Late-Onset:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.37 ATXN2 ATXN3 DRD2 GBA LRRK2 MAOB
2 homeostasis/metabolism MP:0005376 10.33 LRRK2 MAOB MAPT PARK7 PINK1 PRKN
3 cellular MP:0005384 10.23 MAPT PARK7 PINK1 PRKN SLC6A3 SNCA
4 growth/size/body region MP:0005378 10.21 ADH1C ATXN2 DRD2 GBA MAPT PARK7
5 cardiovascular system MP:0005385 10.13 DRD2 GBA LRRK2 MAPT PINK1 PRKN
6 mortality/aging MP:0010768 10.13 SLC6A3 SNCA TBP TH VPS35 ADH1C
7 nervous system MP:0003631 10.13 DRD2 GBA LRRK2 MAOB MAPT PARK7
8 integument MP:0010771 9.97 DRD2 GBA LRRK2 MAPT PRKN SLC6A3
9 no phenotypic analysis MP:0003012 9.81 PRKN SNCA TBP TH VPS35 DRD2
10 normal MP:0002873 9.56 DRD2 GBA LRRK2 MAPT SLC6A3 SNCA
11 taste/olfaction MP:0005394 9.02 DRD2 MAPT PINK1 SLC6A3 SNCA

Drugs & Therapeutics for Parkinson Disease, Late-Onset

Drugs for Parkinson Disease, Late-Onset (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 522)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Rasagiline Approved Phase 4,Phase 2,Phase 3,Phase 1 136236-51-6 3052776
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
Nicotine Approved Phase 4,Phase 2,Phase 1 54-11-5 942 89594
Bromocriptine Approved, Investigational Phase 4,Phase 3,Phase 2 25614-03-3 31101
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
Pramipexole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 104632-26-0 59868 119570
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 91374-20-8, 91374-21-9 5095 497540
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-92-7 6047
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2 123441-03-2 77991
Amantadine Approved Phase 4,Phase 3,Phase 2,Phase 1 768-94-5 2130
Carbidopa Approved Phase 4,Phase 3,Phase 2,Phase 1 28860-95-9 34359 38101
Entacapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130929-57-6 5281081
14 Piracetam Approved Phase 4,Phase 2 7491-74-9
Apomorphine Approved, Investigational Phase 4,Phase 3,Phase 2 41372-20-7, 58-00-4 6005
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Armodafinil Approved, Investigational Phase 4,Phase 2,Early Phase 1 112111-43-0
Modafinil Approved, Investigational Phase 4,Phase 2,Early Phase 1 68693-11-8 4236
Zonisamide Approved, Investigational Phase 4,Phase 2,Phase 3 68291-97-4 5734
Varenicline Approved, Investigational Phase 4,Phase 2 249296-44-4 5310966
Galantamine Approved Phase 4,Phase 2 357-70-0 9651 908828, 9651
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
Selegiline Approved, Investigational, Vet_approved Phase 4,Phase 2 14611-51-9 26757 5195
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2 16590-41-3 5360515
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
Methylphenidate Approved, Investigational Phase 4,Phase 2,Early Phase 1 113-45-1 4158
Norepinephrine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-41-2 439260
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
Trimethobenzamide Approved Phase 4,Phase 1 138-56-7 5577
Midodrine Approved Phase 4,Phase 1 133163-28-7, 42794-76-3 4195
Atenolol Approved Phase 4 29122-68-7 2249
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
Trandolapril Approved Phase 4 87679-37-6 5484727
Verapamil Approved Phase 4 52-53-9 2520
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23651-95-8 443940
Mirabegron Approved Phase 4 223673-61-8
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
Suvorexant Approved Phase 4 1030377-33-3
Tetrabenazine Approved Phase 4 58-46-8 6018
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
Amitriptyline Approved Phase 4 50-48-6 2160
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
Propranolol Approved, Investigational Phase 4 525-66-6 4946

Interventional clinical trials:

(show top 50) (show all 2044)
id Name Status NCT ID Phase
1 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status NCT01007630 Phase 4
2 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
3 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4
4 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 Phase 4
5 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4
6 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status NCT00696215 Phase 4
7 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4
8 Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease Unknown status NCT01673724 Phase 4
9 Emotion, Mood and Executive Function in Parkinson`s Disease (PD) Unknown status NCT01385735 Phase 4
10 Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area Unknown status NCT01782638 Phase 4
11 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4
12 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4
13 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4
14 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
15 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4
16 The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy Unknown status NCT01313819 Phase 4
17 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Unknown status NCT01683253 Phase 4
18 Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Unknown status NCT00142259 Phase 4
19 Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off Completed NCT00391898 Phase 4
20 Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease Completed NCT00219284 Phase 4
21 Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy Completed NCT01782222 Phase 4
22 Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease Completed NCT01032486 Phase 4
23 Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease Completed NCT01723228 Phase 4
24 Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease Completed NCT01049984 Phase 4
25 Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit Completed NCT00272688 Phase 4
26 Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease Completed NCT00914134 Phase 4
27 Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease Completed NCT00153972 Phase 4
28 Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD) Completed NCT00321854 Phase 4
29 Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients Completed NCT01523301 Phase 4
30 A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease Completed NCT01485172 Phase 4
31 Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease Completed NCT00646204 Phase 4
32 Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States Completed NCT00143026 Phase 4
33 Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease Completed NCT01168596 Phase 4
34 Rasagiline and Apathy in Parkinson's Disease Completed NCT00755027 Phase 4
35 Amitiza in Constipation Associated With PD (Parkinson's Disease) Completed NCT00908076 Phase 4
36 Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms Completed NCT01300819 Phase 4
37 Virtual Exercises in Patients With Parkinson's Disease. Completed NCT02023034 Phase 4
38 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease Completed NCT00640159 Phase 4
39 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4
40 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain Completed NCT01744496 Phase 4
41 Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline Completed NCT00902941 Phase 4
42 Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease Completed NCT01018264 Phase 4
43 Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease Completed NCT01313845 Phase 4
44 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4
45 Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease Completed NCT00095810 Phase 4
46 Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment Completed NCT00651183 Phase 4
47 Mild Cognitive Impairment in Parkinson's Disease Completed NCT01519271 Phase 4
48 Donepezil to Treat Dementia in Parkinson's Disease Completed NCT00030979 Phase 4
49 A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery Completed NCT00594464 Phase 4
50 A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients Completed NCT00402233 Phase 4

Search NIH Clinical Center for Parkinson Disease, Late-Onset

Inferred drug relations via UMLS 69 / NDF-RT 48 :

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Parkinson Disease, Late-Onset cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: parkinson disease

Genetic Tests for Parkinson Disease, Late-Onset

Genetic tests related to Parkinson Disease, Late-Onset:

id Genetic test Affiliating Genes
1 Parkinson Disease 29 24 VPS35
2 Parkinson Disease, Late-Onset 29

Anatomical Context for Parkinson Disease, Late-Onset

MalaCards organs/tissues related to Parkinson Disease, Late-Onset:

Brain, Testes, Skin, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Parkinson Disease, Late-Onset:
id Tissue Anatomical CompartmentCell Relevance
1 Brain Substantia Nigra pars Compacta Adult Dopaminergic Neurons Potential therapeutic candidate, affected by disease
2 Brain Forebrain White Matter Fibrous Astrocyte Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
4 Brain Neocortex Protoplasmic Astrocyte Cells Potential therapeutic candidate
5 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Parkinson Disease, Late-Onset

Variations for Parkinson Disease, Late-Onset

UniProtKB/Swiss-Prot genetic disease variations for Parkinson Disease, Late-Onset:

id Symbol AA change Variation ID SNP ID
1 PRKN p.Cys253Tyr VAR_019749 rs747427602
2 PRKN p.Arg256Cys VAR_019750 rs150562946
3 PRKN p.Arg275Trp VAR_019752 rs34424986
4 PRKN p.Asp280Asn VAR_019753 rs72480422

ClinVar genetic disease variations for Parkinson Disease, Late-Onset:

6 (show all 17)
id Gene Variation Type Significance SNP ID Assembly Location
1 ATXN3 NM_004993.5(ATXN3): c.892_894CAG(8_36) (p.Gln298_Gln305=) NT expansion Pathogenic,risk factor rs193922928 GRCh37 Chromosome 14, 92537355: 92537357
2 GBA NM_000157.3(GBA): c.1448T> C (p.Leu483Pro) single nucleotide variant Pathogenic,risk factor rs421016 GRCh37 Chromosome 1, 155205043: 155205043
3 GBA NM_001005741.2(GBA): c.1226A> G (p.Asn409Ser) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs76763715 GRCh37 Chromosome 1, 155205634: 155205634
4 GBA NM_000157.3(GBA): c.1504C> T (p.Arg502Cys) single nucleotide variant Pathogenic,risk factor rs80356771 GRCh37 Chromosome 1, 155204987: 155204987
5 GBA NM_001005741.2(GBA): c.1444G> A (p.Asp482Asn) single nucleotide variant risk factor rs75671029 GRCh37 Chromosome 1, 155205047: 155205047
6 ATXN8OS NR_002717.2(ATXN8OS): n.1103_1105CTG(15_40) NT expansion Pathogenic,risk factor rs193922930 GRCh37 Chromosome 13, 70713516: 70713518
7 ATXN2 NM_002973.3(ATXN2): c.496_498CAG(15_24) (p.Gln188_Pro189insGlnGln) NT expansion risk factor rs193922927 GRCh37 Chromosome 12, 112036785: 112036787
8 TBP NM_003194.4(TBP): c.172_174CAG(25_42) (p.Gln95(25_42)) NT expansion Pathogenic,risk factor rs193922935 GRCh37 Chromosome 6, 170870996: 170870998
9 MT-ND1 m.3397A> G single nucleotide variant Pathogenic rs199476120 GRCh37 Chromosome MT, 3397: 3397
10 GLUD2 NM_012084.3(GLUD2): c.1492T> G (p.Ser498Ala) single nucleotide variant Pathogenic rs9697983 GRCh37 Chromosome X, 120183030: 120183030
11 MAPT NM_016835.4(MAPT): c.1838_1840delATA (p.Asn613del) deletion Pathogenic,risk factor rs63751392 GRCh37 Chromosome 17, 44087740: 44087742
12 VPS13C NM_020821.2(VPS13C): c.9568G> T (p.Glu3190Ter) single nucleotide variant Pathogenic rs869312810 GRCh37 Chromosome 15, 62174851: 62174851
13 VPS13C NM_020821.2(VPS13C): c.8445+2T> G single nucleotide variant Pathogenic rs869312809 GRCh37 Chromosome 15, 62207830: 62207830
14 VPS13C NM_020821.2(VPS13C): c.4777delC (p.Gln1593Lysfs) deletion Pathogenic rs869312811 GRCh37 Chromosome 15, 62239491: 62239491
15 VPS13C NM_020821.2(VPS13C): c.4165G> C (p.Gly1389Arg) single nucleotide variant Pathogenic rs369100678 GRCh37 Chromosome 15, 62250807: 62250807
16 VPS13C NM_020821.2(VPS13C): c.806_807insCAGA (p.Arg269Serfs) insertion Pathogenic rs879253853 GRCh37 Chromosome 15, 62305256: 62305257
17 LRRK2 NM_198578.3(LRRK2): c.4321C> A (p.Arg1441Ser) single nucleotide variant Pathogenic rs33939927 GRCh37 Chromosome 12, 40704236: 40704236

Copy number variations for Parkinson Disease, Late-Onset from CNVD:

7 (show all 18)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 23691 1 173049146 173078950 Copy number PAPPA2 Parkinson disease
2 27433 1 20832534 20850591 Genomic rearrangemen ts PINK1 Parkinson disease
3 60306 11 84948993 84958207 Copy number DLG2 Parkinson disease
4 115237 17 55581582 55809920 Copy number USP32 Parkinson disease
5 132540 19 59310648 59326954 Genomic rearrangemen ts PRPF31 Parkinson disease
6 170895 3 161200000 193800000 Copy number EIF4G1 Parkinson disease
7 186570 4 36900000 88200000 Duplication or tripl ication SNCA Parkinson disease
8 187375 4 48300000 99100000 Copy number SNCA Parkinson disease
9 189219 4 71528873 71716513 Copy number ENAM Parkinson disease
10 190419 4 88200000 94000000 Triplication SNCA Parkinson disease
11 190793 4 90645250 90759447 Duplication SNCA Parkinson disease
12 190807 4 90865727 90978470 Duplication or tripl ication SNCA Parkinson disease
13 195489 5 151389412 151513092 Copy number GLRA1 Parkinson disease
14 207784 6 161000000 164500000 Gain or loss PARK2 Parkinson disease
15 207856 6 161768590 163148834 Copy number PARK2 Parkinson disease
16 207937 6 162471089 162677104 Copy number PARK2 Parkinson disease
17 211738 6 336751 356443 Deletion IRF4 Parkinson disease
18 237664 8 25038472 25171648 Copy number Parkinson disease

Expression for Parkinson Disease, Late-Onset

Search GEO for disease gene expression data for Parkinson Disease, Late-Onset.

Pathways for Parkinson Disease, Late-Onset